GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BIAF · Dec 31, 2025

bioAffinity Technologies, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001493152-26-010143General Corporate
Capex intensity50thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.98% · OPTIONAL · VALID

Operating cash generation38thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-151.39% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-34.18% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure38thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

0.87% · OPTIONAL · VALID

Operating margin25thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-171.58% · CORE · VALID

R&D intensity63thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

22.45% · OPTIONAL · VALID

SBC intensity38thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

10.90% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building
Dec 31, 20240/7 normalizedLevel 3Mar 31, 20250/7 normalizedLevel 3Jun 30, 20250/7 normalizedLevel 3Sep 30, 20250/7 normalizedLevel 3Dec 31, 20256/7 normalizedLevel 3Mar 31, 20266/7 normalizedLevel 3Jun 30, 20266/7 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
-0.25%
Current
0.98%
Delta
1.24%
Cash Generation Increased
Previous
-171.52%
Current
-151.39%
Delta
20.13%
Growth Increased
Previous
-38.48%
Current
-34.18%
Delta
4.29%
Inventory Pressure Decreased
Previous
2.44%
Current
0.87%
Delta
-1.57%
Profitability Decreased
Previous
-158.56%
Current
-171.58%
Delta
-13.02%
R And D Intensity Decreased
Previous
22.86%
Current
22.45%
Delta
-0.41%
Sbc Intensity Increased
Previous
4.64%
Current
10.90%
Delta
6.25%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · BIAF Fundamental State →Has State · bioAffinity Technologies, Inc. →Transitioned To · BIAF Fundamental State →Transitioned To · BIAF CAPEX_INTENSITY_INCREASED →Transitioned To · BIAF CASH_GENERATION_INCREASED →Transitioned To · BIAF GROWTH_INCREASED →Transitioned To · BIAF INVENTORY_PRESSURE_DECREASED →Transitioned To · BIAF PROFITABILITY_DECREASED →Transitioned To · BIAF R_AND_D_INTENSITY_DECREASED →Transitioned To · BIAF SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.